Literature DB >> 34033528

COVID-19 vaccine platforms: Delivering on a promise?

Mark Verdecia1, John F Kokai-Kun1, Maura Kibbey1, Sarita Acharya1, Jaap Venema1, Fouad Atouf1.   

Abstract

The emergence of the novel SARS-CoV-2 and COVID-19 has brought into sharp focus the need for a vaccine to prevent this disease. Vaccines have saved millions of lives since their introduction to the public over 200 years ago. The potential for vaccination reached new heights in the mid-20th century with the development of technologies that expanded the ability to create novel vaccines. Since then, there has been continued technological advancement in vaccine development. The resulting platforms provide the promise for solutions for many infectious diseases, including those that have been with us for decades as well as those just now emerging. Each vaccine platform represents a different technology with a unique set of advantages and challenges, especially when considering manufacturing. Therefore, it is essential to understand each platform as a separate product and process with its specific quality considerations. This review outlines the relevant platforms for developing a vaccine for SARS-CoV-2 and discusses the advantages and disadvantages of each.

Entities:  

Keywords:  COVID-19; manufacturing; platform development; vaccines

Year:  2021        PMID: 34033528     DOI: 10.1080/21645515.2021.1911204

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  4 in total

Review 1.  An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.

Authors:  Bulent Kantarcioglu; Omer Iqbal; Joseph Lewis; Charles A Carter; Meharvan Singh; Fabio Lievano; Mark Ligocki; Walter Jeske; Cafer Adiguzel; Grigoris T Gerotziafas; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

2.  Production and characterization of chimeric SARS-CoV-2 antigens based on the capsid protein of cowpea chlorotic mottle virus.

Authors:  Claudia Almendárez-Rodriguez; Karla I Solis-Andrade; Dania O Govea-Alonso; Mauricio Comas-Garcia; Sergio Rosales-Mendoza
Journal:  Int J Biol Macromol       Date:  2022-06-08       Impact factor: 8.025

3.  Points to consider for COVID-19 vaccine quality control and national lot release in Republic of Korea: focus on a viral vector platform.

Authors:  Jung Hun Ju; Naery Lee; Sun-Hee Kim; Seokkee Chang; Misook Yang; Jihyun Shin; Eunjo Lee; Sunhwa Sung; Jung-Hwan Kim; Jin Tae Hong; Ho Jung Oh
Journal:  Osong Public Health Res Perspect       Date:  2022-02-08

4.  Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis.

Authors:  Becky Mingyao Ma; Anthony Raymond Tam; Kam Wa Chan; Maggie Kam Man Ma; Ivan Fan Ngai Hung; Desmond Yat Hin Yap; Tak Mao Chan
Journal:  Front Med (Lausanne)       Date:  2022-03-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.